Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Ambrx and Bristol-Myers Squibb have agreed to discover and develop antibody-drug conjugates using Ambrx’ protein medicinal chemistry technology. In exchange for commercial rights, BMS will supply Ambrx $15 million up front, R&D funding, and up to $97 million per product upon reaching certain milestones. The two companies have worked together since September 2011 on the discovery of biologic drugs. As a result of that work, BMS is currently developing a potential diabetes drug and a heart failure treatment.
This article has been sent to the following recipient: